Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report

被引：0

作者：

Torres, Viviana ^{[1
]}

Gonzalez-Ortega, Guillermo ^{[1
]}

Suarez, Antoni ^{[1
]}

Garrido, Alicia ^{[1
,2
,3
,4
,5
]}

Camara, Ana ^{[1
,2
]}

Compta, Yaroslau ^{[1
,2
,3
,4
,5
]}

Valldeoriola, Francesc ^{[1
,2
,3
,4
,5
]}

机构：

[1] Hosp Clin Barcelona, Inst Neurociencies, Neurol Serv, Parkinsons Dis & Movement Disorders Unit, Catalonia, Spain

[2] Univ Barcelona, Neurol Serv, Parkinsons Dis & Movement Disorders Unit, Hosp Clin 1, Barcelona, Spain

[3] Univ Barcelona, Inst Clin Neurociencies, Maria Maeztu Excellence Ctr, IDIBAPS,ERN RND,CIBERNED,ISCIII, CB06 05 0018, Barcelona, Catalonia, Spain

[4] Lab Parkinson Dis & Other Neurodegenerat Movement, Barcelona, Spain

[5] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Inst Neurociencies,Dept Neurol, Barcelona, Catalonia, Spain

来源：

CLINICAL PARKINSONISM & RELATED DISORDERS | 2022年 / 7卷

关键词：

D O I：

10.1016/j.prdoa.2022.100150

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.

引用

页数：2

共 50 条

[21] Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)
Kovacs, Norbert
Szasz, Jozsef
Vela-Desojo, Lydia
Svenningsson, Per
Femia, Samira
Parra, Juan Carlos
Sanchez-Solino, Olga
Bergmann, Lars
Gurevich, Tanya
Fasano, Alfonso
PARKINSONISM & RELATED DISORDERS, 2022, 105 : 139 - 144
[22] Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to Levodopa-Carbidopa Intestinal Gel delivered to the jejunum
Rosebraugh, Matthew
Stodtmann, Sven
Liu, Wei
Facheris, Maurizio
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 331 - 331
[23] Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum
Rosebraugh, Matthew
Stodtmann, Sven
Liu, Wei
Facheris, Maurizio F.
PARKINSONISM & RELATED DISORDERS, 2022, 97 : 68 - 72
[24] Foslevodopa/foscarbidopa Subcutaneous Infusion Maintains Equivalent Levodopa Exposure to Levodopa-Carbidopa Intestinal Gel Delivered to the Jejunum
Rosebraugh, Matthew
Stodtmann, Sven
Liu, Wei
Facheris, Maurizio
NEUROLOGY, 2021, 96 (15)
[25] A case of Perry Syndrome responding to intestinal infusion of carbidopa/levodopa
Hamed, Moath
Shetty, Aakash
Tremain, Genise
Lazarescu, Adriana
Suchowersky, Oksana
PARKINSONISM & RELATED DISORDERS, 2019, 61 : 236 - 237
[26] Efficacy of Levodopa-Carbidopa Intestinal Gel Versus Oral Levodopa-Carbidopa in Advanced Parkinson's: Sensitivity and Responder Analyses
Boyd, James T.
Fernandez, Hubert H.
Slevin, John T.
Espay, Alberto J.
Standaert, David G.
Pritchett, Yili
Zhang, Wuyan
Chatamra, Krai
Widnell, Katherine L.
Benesh, Janet
ANNALS OF NEUROLOGY, 2013, 74 : S44 - S44
[27] Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
Constantin, Viorelia Adelina
Szasz, Jozsef Attila
Orban-Kis, Karoly
Rosca, Elena Cecilia
Popovici, Maria
Cornea, Amalia
Bancu, Ligia Ariana
Ciorba, Marius
Mihaly, Istvan
Nagy, Elod
Szatmari, Szabolcs
Simu, Mihaela
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 1835 - 1844
[28] Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease
Meloni, Mario
Solla, Paolo
Mascia, Marcello Mario
Marrosu, Francesco
Cannas, Antonino
PARKINSONISM & RELATED DISORDERS, 2017, 37 : 92 - 96
[29] Long-term levodopa-carbidopa intestinal infusion in Parkinson's disease: survival and mortality
Artusi, C. A.
Balestrino, R.
Imbalzano, G.
Bortolani, S.
Tuttobene, S.
Montanaro, E.
Zibetti, M.
Lopiano, L.
MOVEMENT DISORDERS, 2019, 34 : S27 - S27
[30] Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients
Klostermann, Fabian
Bojarski, Christian
Marzinzik, Frank
Maier, Andre
Schindlbeck, Katharina A.
Ehlen, Felicitas
MOVEMENT DISORDERS, 2017, 32 (02) : 300 - 301

← 1 2 3 4 5 →